Point-of-care test offers alternative to biopsy for UC diagnosis, monitoring

  • Nakov RV & al.
  • Folia Med (Plovdiv)
  • 1 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Fecal calprotectin (FCP) testing offers a noninvasive alternative to endoscopy with biopsy for diagnosing and monitoring ulcerative colitis (UC) disease activity.

Why this matters

  • The test is simple and fast, and can be performed at the point of care without special equipment.

Study design

  • Researchers studied patients with either active or quiescent UC undergoing colonoscopy (n=116; 55.17% men; mean age, 38.9±9 years; age range, 18-63 years), comparing them with a control group of patients with irritable bowel syndrome (IBS; n=36).
  • They graded colonoscopy findings using the Mayo endoscopic score (EMS) and UC endoscopic index of severity (UCEIS) and analyzed FCP levels in stool samples collected within 2 days before colonoscopy.
  • Funding: None.

Key results

  • Researchers found no significant difference between mean FCP levels in the UC group and those in patients with IBS or in UC remission (P=.205).
  • In contrast, mean FCP levels were significantly higher in patients with active UC (P<.001>
  • Mean FCP levels correlated significantly with UCEIS (Pearson correlation coefficient [r]=0.869; P<.001 and ems p>

Limitations

  • The study was single-center with a small sample size.